Treatment of depression with escitalopram: Results of a large post-marketing surveillance study;Behandlung der depression mit escitalopram: Ergebnisse einer großen anwendungsbeobachtung

Psychopharmakotherapie

Volumn 14, Issue 4, 2007, Pages 149-156

  Möller, Hans Jürgen ^a   Friede, Michael ^b   Schmauß, Max ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Lundbeck GmbH   (Germany)

^c Bezirkskrankenhaus Augsburg   (Germany)

Author keywords

Cipralex ; Citalopram; Depression; Escitalopram

Indexed keywords

ESCITALOPRAM;

ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL GLOBAL IMPRESSION SCALE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENERALIZED ANXIETY DISORDER; HUMAN; MAJOR DEPRESSION; NAUSEA; OUTCOME ASSESSMENT; PANIC; POSTMARKETING SURVEILLANCE; SCORING SYSTEM; SOCIAL PHOBIA; TREATMENT OUTCOME; VERTIGO;

EID: 34547698769     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Alexopoulos GS, Privitera W, Ventura D, Bose A, et al. Fixed dose of escitalopram (10 mg/day) and a flexible dosing regimen of sertraline (50-200 mg/day) in a randomised, double blind comparison in depressed patients [Poster]. International Congress of Biological Psychiatry February 9-11, 2004, Sydney, Australia.
2. Auquier P, Robtail S, Llorca P-M, Rive B. Comparison of escitalopram and citalopram efficacy: A meta-analysis. Int J Psychiatry Clin Prac 2003;7:259-68.
3. Bielski RJ, Ventura D, Chang C-C. A double-blind comparison of escitalopram and ven-lafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004;65:1190-6.
4. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63:331-6.
5. th European College of Neuropsychopharmacology (ECNP), Prague, Czech Republic, 20-24 September 2003.
6. rd International Forum on Mood and Anxiety Disorders, Monte Carlo, Monaco, November 27-30, 2002.
7. Einarson TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int Clin Psychopharmacol 2004;19:305-10.
8. Fachinformation zu CIPRALEX® 10 mg und CIPRALEX® 20 mg Filmtabletten. Lundbeck GmbH, Oktober 2005.
9. Gorman JM, Kent JM. SSRIs and SNRIs: broad spectrum of efficacy beyond major depression. J Clin Psychiatry 1999;60(Suppl 4):33-8.
10. Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectrums 2002;7:40-4.
11. th World Congress of Biological Psychiatry (WCBP), Berlin, Germany, July 1-6, 2001.
12. Hyttel J, Bøgesø KP, Perregaard J, et al. The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. J Neural Transm Gen Sect 1992;88:157-60.
13. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994;9(Suppl 1):19-26.
14. Isaac M. Where are we going with SSRIs? Eur Neuropsychopharmacol 1999;9(Suppl 3):101-6.
15. Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003;18:211-7.
16. Llorca JM, Azorin JM, Despiegel N, Verpillat P. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Practice 2005;59:268-75.
17. Mitchell PJ, Hogg S. Behavioral effects of escitalopram predict rapid antidepressant activity. Biol Psychiatry 2001;49(Suppl):115S (abstract no. 401).
18. Möller HJ. Antidepressants - do they decrease or increase suicidally? Pharmacopsychiatry 1992;25:249-53.
19. Möller HJ. Evidence for beneficial effects of antidepressants on suicidality in depressive patients. Eur Arch Psychiatry Clin Neurosci 2006;256:329-43.
20. Möller HJ, Schnitker J. sv-MADRS in einer prospektiven Kohortenstudie zur Depression [Poster]. DGPPN-Kongress, 22.-25. November 2006, Berlin, Deutschland.
21. Montgomery SA, Loft H, Sanchez C, et al. Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicol 2001;88:282-6.
22. Montgomery SA, Huusom AKT, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychology 2004;50:57-64.
23. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005;20:131-7.
24. Mørk A, Kreilgaard M, Sanchez C. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 2003;45:167-73.
25. th Annual Meeting of the American Psychiatric Association, San Francisco, USA, May 17-22, 2003.
26. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001;50:345-50.
27. Pirker W, Asenbaum S, Kasper S, et al. Beta-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J Neural Transm Gen Sect 1995;100:247-56.
28. Rausch JL, Corley KM, Hobby HM. Improved potency of escitalopram of the human serotonin transporter. J Clin Psychopharmacol 2004;24:209-13.
29. Sánchez C, Bergqvist PBF, Brennum LT, Gupta S, et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects of animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology 2003;167:353-62.
30. Sánchez C, B́gesø K, Ebert B, Heldbo Reines E, et al. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology 2004;174:163-76.
31. Sánchez C, Kreilgaard M. R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav 2004;77,391-8.
32. Wade AG, Lemming O, Hedegaard K. Escitalopram 10 mg/day is effective and well-tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002;17:95-102.
33. Winkler D, Pirek E, Klein N, Kasper S. Escitalopram bei berufstatigen Menschen. Ergebnisse einer Anwendungsbeobachtung an 2 378 Patienten. Psychopharmakotherapie 2006;13:142-6.